LT group | PH group | |||||||
Imaging | Stage I | Stage II | Stage III | Overall | Stage I | Stage II | Stage III | Overall |
Contrast CT | 69.2% (9/13) | 37.5% (3/8) | 0.0% (0/1) | 54.5% (12/22) | 37.5% (6/16) | 0.0% (0/3) | 0.0% (0/2) | 28.6% (6/21) |
18F-FDG PET/CT | 23.1% (3/13) | 0.0% (0/8) | 100.0% (1/1) | 18.2% (4/22) | 37.5% (6/16) | 0.0% (0/3) | 50.0% (1/2) | 33.3% (7/21) |
11C-ACT PET/CT | 92.3% (12/13) | 87.5% (7/8) | 100.0% (1/1) | 90.9% (20/22) | 100.0% (16/16) | 66.7% (2/3) | 50.0% (1/2) | 90.5% (19/21) |
Dual-tracer PET/CT | 92.3% (12/13) | 87.5% (7/8) | 100.0% (1/1) | 90.9% (20/22) | 100.0% (16/16) | 66.7% (2/3) | 50.0% (1/2) | 90.5% (19/21) |
↵* Pathologic analysis was used as reference standard.